Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Robinson

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2023
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical ModelsGonzalo Rodriguez-Berriguete, Marco Ranzani, Remko Prevo, et al.
Science Advances|June 12, 2026
<i>SHLD2</i> loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapyGonzalo Rodriguez-Berriguete, Purusotha Thambiayah, Alessandro Cicconi, et al.
Nucleic Acids Research|December 8, 2025
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapyEeson Rajendra, Claudio A Lademann, Bethany Mason, et al.
Journal of Medicinal Chemistry|December 8, 2025
Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1Sam E Mann, Owen A Davis, Jörg Bomke, et al.
Journal of Medicinal Chemistry|October 6, 2022
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase ThetaMartin L Stockley, Amanda Ferdinand, Giovanni Benedetti, et al.
Journal of Medicinal Chemistry|December 4, 2024
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid CancersChristopher L Carroll, Michael G Johnson, Yanbing Ding, et al.
Journal of Medicinal Chemistry|February 23, 2023
Correction to "Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta"Martin L Stockley, Giovanni Benedetti, Peter Blencowe, et al.
Journal of Medicinal Chemistry|September 17, 2025
Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 InhibitorSam E Mann, Julien Lefranc, Omar Alkhatib, et al.
Nature Communications|June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor TypesPatrick G Pilié, Virginia Giuliani, Wei-Lien Wang, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2023
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical ModelsGonzalo Rodriguez-Berriguete, Marco Ranzani, Remko Prevo, et al.
Science Advances|June 12, 2026
<i>SHLD2</i> loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapyGonzalo Rodriguez-Berriguete, Purusotha Thambiayah, Alessandro Cicconi, et al.
Nucleic Acids Research|December 8, 2025
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapyEeson Rajendra, Claudio A Lademann, Bethany Mason, et al.
Journal of Medicinal Chemistry|December 8, 2025
Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1Sam E Mann, Owen A Davis, Jörg Bomke, et al.
Journal of Medicinal Chemistry|October 6, 2022
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase ThetaMartin L Stockley, Amanda Ferdinand, Giovanni Benedetti, et al.
Journal of Medicinal Chemistry|December 4, 2024
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid CancersChristopher L Carroll, Michael G Johnson, Yanbing Ding, et al.
Journal of Medicinal Chemistry|February 23, 2023
Correction to "Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta"Martin L Stockley, Giovanni Benedetti, Peter Blencowe, et al.
Journal of Medicinal Chemistry|September 17, 2025
Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 InhibitorSam E Mann, Julien Lefranc, Omar Alkhatib, et al.
Nature Communications|June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor TypesPatrick G Pilié, Virginia Giuliani, Wei-Lien Wang, et al.
Pageof 14